Like so many other pharmaceutical stocks, Novartis (NYSE:NVS) has done pretty well for its shareholders over the past year and solidly beat the S&P 500.
With that move, the multi-year discount in most Big Pharma shares has
evaporated and Novartis is no exception. Novartis has a deep and
high-potential pipeline, but threats from generic competition,
competition to its branded drugs, margin pressure, and strategic
uncertainties do mitigate some of that pipeline value.
To read more, please follow this link:
http://www.investopedia.com/stock-analysis/061213/after-good-run-novartis-looks-fairly-valued-nvs-rhhby-bmy-mrk-biib.aspx
No comments:
Post a Comment